Alzheon
Alzheon, Inc. is a privately held clinical-stage biopharmaceutical company founded in 2013 and headquartered at 111 Speen Street, Framingham, Massachusetts, developing oral small-molecule therapeutics and diagnostics for Alzheimer's disease and other neurodegenerative disorders. Its lead candidate, valiltramiprosate (ALZ-801) — a valine-conjugated prodrug of tramiprosate that blocks the formation of neurotoxic soluble beta-amyloid oligomers — has FDA Fast Track designation and completed the pivotal APOLLOE4 Phase 3 trial in APOE4/4 homozygotes with early Alzheimer's disease. Alzheon operates no product or developer API and publishes no developer portal, SDKs or API documentation; its corporate site does serve the standard WordPress REST API anonymously, which makes its press releases, science pages and media library machine-readable.
Alzheon publishes 1 API on the APIs.io network: Content API (WordPress REST). Tagged areas include Company, Biotechnology, Pharmaceuticals, Life Sciences, and Clinical Trials.
Alzheon’s developer surface includes engineering blog, product news, and 15 more developer resources.
Kin Score
APIs 1
Individual APIs this provider publishes, each with its own machine-readable definition.
Alzheon Content API (WordPress REST)
Read-only, anonymously accessible WordPress REST API served by the Alzheon corporate site at https://alzheon.com/wp-json. It exposes the company's press releases and in-the-news...
Security Posture 2
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Agent Surfaces 3
MCP servers, agent skills, and machine-readable catalogs
Access & Security 1
Authentication, authorization, and security posture
Operate 1
Status, limits, changes, and where to get help
Commercial 1
Pricing, plans, and the legal terms of use
Company 8
The organization behind the API
Scroll for all 8
Other 3
Properties that don't map to a standard resource type